The Union Budget 2025 has been highly anticipated by various sectors, including the pharmaceutical and healthcare industries. As India continues to position itself as a global pharma leader, government policies and budget allocations play a crucial role in shaping its growth trajectory. This year’s budget was expected to address key challenges such as research and development (R&D) funding, manufacturing incentives, drug pricing regulations, and accessibility of healthcare.
In recent years, India’s pharmaceutical industry has grown to become the third-largest globally by volume and 14th by value, with a market size of approximately $50 billion. The government's proactive stance on healthcare and pharma, particularly through initiatives like Ayushman Bharat and the Production-Linked Incentive (PLI) scheme, has strengthened the sector’s foundation. With this budget, the industry hoped for further support in key areas, including investment in drug innovation, tax relief, infrastructure development, and global market expansion.
